Medical management of metastatic bone disease

Curr Opin Support Palliat Care. 2010 Sep;4(3):189-94. doi: 10.1097/SPC.0b013e32833d3024.


Purpose of review: To highlight recent advances in the medical management of metastatic bone disease.

Recent findings: Progress has been made in quality of life assessment and pain measurement; in novel ways to use bisphosphonates, especially in the adjuvant setting for prevention of bone metastases and in combination with other pharmaceutical agents, where synergistic enhancement holds high potential; in targeted therapies using novel agents, especially with denosumab which is approaching registration; in the use of bone biomarkers to direct therapy and as surrogate endpoints; in development of radiopharmaceuticals for improved treatment of disseminated bone pain.

Summary: Metastatic bone disease continues to present management challenges, but these challenges are being met with an increased armamentarium of available interventions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Bone Density Conservation Agents / therapeutic use
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / psychology
  • Bone Neoplasms / surgery
  • Denosumab
  • Diphosphonates / therapeutic use
  • Humans
  • Hypercalcemia / drug therapy
  • Neoplasm Metastasis / drug therapy
  • Neoplasm Metastasis / prevention & control
  • Pain / drug therapy*
  • Pain / psychology
  • Quality of Life / psychology
  • RANK Ligand / therapeutic use
  • Risk Reduction Behavior


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biomarkers, Tumor
  • Bone Density Conservation Agents
  • Diphosphonates
  • RANK Ligand
  • Denosumab